"Adenosine Monophosphate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Adenine nucleotide containing one phosphate group esterified to the sugar moiety in the 2'-, 3'-, or 5'-position.
| Descriptor ID |
D000249
|
| MeSH Number(s) |
D03.633.100.759.646.138.180 D13.695.667.138.180 D13.695.827.068.180
|
| Concept/Terms |
2'-Adenylic Acid- 2'-Adenylic Acid
- 2' Adenylic Acid
- Acid, 2'-Adenylic
- 2'-Adenosine Monophosphate
- 2' Adenosine Monophosphate
- Monophosphate, 2'-Adenosine
- Adenylic Acid
- 2'-AMP
|
Below are MeSH descriptors whose meaning is more general than "Adenosine Monophosphate".
Below are MeSH descriptors whose meaning is more specific than "Adenosine Monophosphate".
This graph shows the total number of publications written about "Adenosine Monophosphate" by people in this website by year, and whether "Adenosine Monophosphate" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2020 | 2 | 0 | 2 |
| 2021 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Adenosine Monophosphate" by people in Profiles.
-
Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients. N Engl J Med. 2022 01 27; 386(4):305-315.
-
Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021 12; 9(12):1365-1376.
-
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. N Engl J Med. 2021 03 04; 384(9):795-807.
-
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. N Engl J Med. 2020 11 05; 383(19):1827-1837.